Bill > A00044

This bill requires healthcare providers and testing entities to provide comprehensive, clear information about non-invasive prenatal screening (NIPS), which is a type of genetic test used to assess potential chromosomal abnormalities in a fetus. The bill mandates that written notices must be provided to patients before, during, and after prenatal testing, clearly explaining that these screenings are risk assessments and not definitive diagnostic tests. The notices must emphasize that positive or high-risk results do not guarantee the presence of genetic abnormalities, and negative or low-risk results do not definitively rule them out. Additionally, the bill requires the New York State Department of Health to develop and post detailed informational materials on its website in multiple languages, including current recommendations from professional medical organizations like the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG). These materials must outline the benefits and limitations of non-invasive prenatal testing, list approved screening tests, and provide context about their performance characteristics. The bill aims to ensure patients are fully informed about the purpose, capabilities, and potential limitations of these genetic screening tests, while preserving healthcare providers' ability to recommend testing based on individual patient needs.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A44